| 06/28/2008 01:00 AM |
| CONCERTA® Now Available For Patients With ADHD Ages 6 To 65 In USA |
|
ADHD is the most common emotional, cognitive and behavioral disorder treated in children1, and according to the National Institute of Mental Health (NIMH), between 30 percent and 70 percent of children with ADHD continue to exhibit symptoms in the adult years 2.
|
| 06/26/2008 04:00 AM |
| NIMH Funds Pitt Researchers To Find Best Treatments For Children With Autism And ADHD Symptoms |
|
Researchers at the University of Pittsburgh and the Western Psychiatric Institute and Clinic of UPMC have received $3 million from the National Institute of Mental Health to conduct a national study of the treatment of attention deficit hyperactivity disorder (ADHD) in children with autism spectrum disorders.
|
| 06/25/2008 01:00 AM |
| How Ritalin Works In Brain To Boost Cognition, Focus Attention |
|
Stimulant medications such as Ritalin have been prescribed for decades to treat attention deficit hyperactivity disorder (ADHD), and their popularity as "cognition enhancers" has recently surged among the healthy, as well. What's now starting to catch up is knowledge of what these drugs actually do in the brain.
|
| 06/19/2008 12:00 AM |
| Concept Media Releases AD/HD, Autism, And Mental Retardation Programs |
|
Concept Media, a leading producer and distributor of healthcare education media, has just released ADHD: Attention Deficit/Hyperactivity Disorder, Autism Spectrum Disorders, and Mental Retardation in DVD and CD-ROM formats. These new scenario-based series have a multidisciplinary focus that features medicine, nursing, education, and human development.
|
| 06/17/2008 03:00 AM |
| The Gene For ADHD May Have Benefited Our Nomadic Ancestors |
|
An ADHD-associated version of the human gene DRD4 is linked to better health among nomadic tribesmen, but may cause malnourishment in their settled cousins, according to new research by a team directed by an anthropologist at the University of Wisconsin-Milwaukee (UWM).
|
| 06/05/2008 02:00 AM |
| Sciele Pharma Announces That Addrenex Has Completed Enrollment Of Pivotal Phase III Trial For Clonicel For ADHD |
|
Sciele Pharma, Inc. (NASDAQ: SCRX), a specialty pharmaceutical company, announced that Addrenex Pharmaceuticals has completed patient enrollment of its first Phase III clinical trial in the U.S. for Clonicel to treat attention deficit and hyperactivity disorder (ADHD) in children. Addrenex is also continuing to enroll patients in an additional Phase III trial using Clonicel in combination with stimulants such as methylphenidate and dextro-amphetamine/amphetamine to treat ADHD.
|
| 06/05/2008 01:00 AM |
| PsychoGenics Announces Positive Phase-IIa For Its First-in-Class Partial 5-HT1A - 5-HT1B Receptor Agonist In ADHD |
|
PsychoGenics Inc. announced positive data from its randomized, placebo controlled, multicenter, Phase IIa trial of eltoprazine, the company's lead partial 5-HT1A - 5-HT1B receptor agonist, in adult patients with Attention Deficit/ Hyperactivity Disorder (ADHD).
|
| 05/30/2008 06:00 AM |
| Children's Diet Not The Main Cause Of ADHD |
|
Food may not be the major cause of hyperactivity in children. Genetics, brain function and parental actions such as smoking may be just as important. A review of scientific evidence found only a minority of children were actually affected by what they eat. A combination of food, genetics and environmental toxins are more likely to be involved, with no single factor to blame. Foods which might affect behaviour, in particular table sugar were studied.
|
| 05/26/2008 04:00 PM |
| AAP And American Heart Association Clarify Statement On ADHD And Electrocardiograms |
|
The American Heart Association released on April 21, 2008, a statement about cardiovascular evaluation and monitoring of children receiving drugs for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). As a result of language in the news release and the statement as published, there have been conflicting interpretations of the recommendations regarding the use of an electrocardiogram (ECG) in assessing children with ADHD who may need treatment with medications.
|
| 05/19/2008 01:00 AM |
| New European Study Showed OROS(R) Methylphenidate Tablets Significantly Improved Symptoms In Adults With ADHD |
|
Adults with attention deficit hyperactivity disorder (ADHD) treated in an investigational study with OROS® methylphenidate tablets experienced significantly greater improvements in their ADHD symptoms compared to patients taking placebo, according to findings from a trial published in Biological Psychiatry.
|
| 05/10/2008 12:00 AM |
| FDA Approves Strattera(R) For Maintenance Of ADHD In Children And Adolescents |
|
Eli Lilly and Company (NYSE: LLY) announced that the United States Food and Drug Administration (FDA) has approved Strattera(R) (atomoxetine HCI) for maintenance treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents. Strattera, a selective norepinephrine reuptake inhibitor, is the first FDA-approved non-stimulant to treat ADHD in children, adolescents and adults.
|
| 05/09/2008 03:00 AM |
| VYVANSE Demonstrated Significant Improvement In ADHD Symptoms In Adults |
|
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, presented the results of a phase III pivotal study in which VYVANSE demonstrated significant improvements in Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults and met all safety and efficacy endpoints. "Adults with ADHD often find it challenging to focus and organize during the day.
|
| 05/08/2008 06:00 AM |
| Shire Investigational Nonstimulant INTUNIV Showed Significant Efficacy In Reducing ADHD Symptoms |
|
Shire plc(LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, has presented at a major scientific meeting findings from analyses of pivotal trial results of INTUNIV, a selective alpha-2A-agonist. This compound is an investigational once-daily medication, which is being evaluated for the treatment of the symptoms of Attention Deficit Hyperactivity Disorder (ADHD).
|
| 05/08/2008 12:00 AM |
| OROS(R) Methylphenidate In Adults With ADHD: New Insights |
|
Although once considered to be a disorder only seen in children, Attention Deficit Hyperactivity Disorder (ADHD) is now known to be a condition associated with a wide range of functional impairments throughout the lifespan(1). In the US, the overall prevalence of ADHD in adults is estimated to range between 3.4% and 4.4%(2), and between 30 and 70% of children with ADHD continue to exhibit symptoms into adult years(3).
|
| 05/08/2008 12:00 AM |
| New Analysis In Boys And Girls Shows The ADHD Patch, DAYTRANA(TM) (methylphenidate Transdermal System), Offered ADHD Symptom Control For 12 Months |
|
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced findings from a new data analysis that was conducted to examine treatment differences with DAYTRANA(TM) (methylphenidate transdermal system) between boys and girls aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD).
|
| 05/02/2008 01:00 AM |
| Shire To Present Additional Scientific Data On ADHD Treatment Portfolio At American Psychiatric Association Annual Meeting |
|
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments, lisdexamfetamine dimesylate, methylphenidate transdermal system and the investigational non-stimulant treatment under FDA review, guanfacine extended release, at the American Psychiatric Association (APA) annual meeting to be held May 3rd to 8th in Washington, D.C.
|
| 04/28/2008 02:00 AM |
| Sensory Treatment Reduces Autistic Mannerisms |
|
Parents of children with autism are increasingly turning to sensory integration treatment to help their children deal with the disorder, and they're seeing good results. In 2007, 71 percent of parents who pursued alternatives to traditional treatment used sensory integration methods, and 91 percent found these methods helpful.
|
| 04/27/2008 03:00 AM |
| Simplicity Of Working Memory Study Could Help With ADD And Other Attention Difficulties |
|
A mind is a terrible thing to waste, but humans may have even less to work with than previously thought. University of Missouri researchers found that the average person can keep just three or four things in their "working memory" or conscious mind at one time. This finding may lead to better ways to assess and help people with attention-deficit and focus difficulties, improve classroom performance and enhance test scores.
|
| 04/24/2008 12:00 AM |
| FDA Approves VYVANSE(TM) (lisdexamfetamine Dimesylate), The First And Only Once-Daily Prodrug Stimulant To Treat ADHD In Adults |
|
Shire plc (LSE: SHP) (NASDAQ: SHPGY,), the global specialty biopharmaceutical company, announced that it has received approval from the U.S. Food and Drug Administration (FDA) for VYVANSE(TM) (lisdexamfetamine dimesylate), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults.
|
| 04/22/2008 03:00 AM |
| Heart Tests Should Be Carried Out Before Treatment With Stimulant Drugs For Children With ADHD |
|
Children with attention deficit hyperactivity disorder (ADHD) should get careful cardiac evaluation and monitoring - including an electrocardiogram (ECG) - before treatment with stimulant drugs, a new American Heart Association statement recommends. The scientific statement on Cardiovascular Monitoring of Children and Adolescents with Heart Disease Receiving Stimulant Drugs is published online in Circulation: Journal of the American Heart Association.
|
| 04/21/2008 12:00 AM |
| Medication Improves Driving Ability ADHD Patients |
|
The use of the medication methylphenidate considerably improves the driving ability of people with ADHD. This was shown in research done by Joris Verster of Utrecht University, The Netherlands. The study will appear in the May 2008 issue of Journal of Psychopharmacology. People with ADHD are often prescribed methylphenidate (brand name Ritalin) to counteract hyperactive behavior and attention dysfunction that may negatively affect their driving ability.
|
| 03/31/2008 04:00 AM |
| Stimulant Treatment For Young Children With ADHD Does Not Lead To Increased Risk Of Substance Abuse In Early Adulthood |
|
Treatment of children with stimulant medications for attention-deficit/hyperactivity disorder (ADHD) does not increase the risk of substance abuse later in adolescence and early adulthood.
|
| 03/31/2008 03:00 AM |
| Encouraging Preschool Kids To Talk To Themselves |
|
Parents should not worry when their pre-schoolers talk to themselves; in fact, they should encourage it, says Adam Winsler, an associate professor of psychology at George Mason University. His recent study published in Early Childhood Research Quarterly showed that 5-year-olds do better on motor tasks when they talk to themselves out loud (either spontaneously or when told to do so by an adult) than when they are silent.
|
| ADD / ADHD Products |
ADD / ADHD Services |
Learning Disability Resources | Famous ADD/HD People | ADD/ADHD News |
